Hydralazine/isosorbide dinitrate

Drug Profile

Hydralazine/isosorbide dinitrate

Alternative Names: AR-06; BiDil; BiDil XR; Heart failure therapy - NitroMed; Hydralazine hydrochloride/isosorbide dinitrate; Isosorbide dinitrate/hydralazine

Latest Information Update: 18 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NitroMed
  • Developer Arbor Pharmaceuticals; NitroMed
  • Class Heart failure therapies; Organic nitrates; Peripheral vasodilators; Phthalazines; Small molecules
  • Mechanism of Action Antioxidants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Apr 2016 Arbor Pharmaceuticals completes a phase I/II trial in Heart failure in USA (NCT02522208)
  • 01 Sep 2015 Phase-I/II clinical trials in Heart failure in USA (PO, controlled-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top